Last updated: February 22, 2026
What is the Drug and Its Market Status?
NDC 00713-0664 corresponds to Bexarotene Capsule, 75 mg, marketed under the brand name Targretin by Ipsen. Bexarotene is approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have not responded to prior skin-directed therapy.
Market Approval and Population:
- Approved by the FDA in 1999 for CTCL.
- Indications are limited to a niche specialty oncology market.
- The patient population primarily consists of adult CTCL patients resistant to other treatments.
Market Dynamics:
- The global CTCL market was valued at approximately $75 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five years [1].
- Bexarotene faces competition from newer systemic agents, such as histone deacetylase inhibitors and targeted therapies, but retains a niche due to its unique mechanism and specific approval.
Competitive Landscape
| Product Name |
Indication |
Approval Year |
Market Share |
Price (Estimated per capsule) |
| Bexarotene (Targretin) |
CTCL |
1999 |
70% |
$1,200 |
| Vorinostat (Zolinza) |
CTCL, multiple cancers |
2006 |
15% |
$950 |
| Mogamulizumab (Poteligeo) |
CTCL, adult T-cell leukemia/lymphoma |
2018 |
10% |
$8,500 per vial (100 mg) |
| Other systemic agents |
Various, off-label use |
N/A |
5% |
Varies |
Note: Bexarotene's higher per-unit cost reflects formulation complexity and the scarcity of generic options.
Price Trajectory and Trends
| Year |
Average Price per Capsule |
Key Factors |
| 2018 |
$1,150 |
Launch of new formulations, patent protections maintained |
| 2020 |
$1,200 |
No significant generic competition, market stability |
| 2022 |
$1,200 |
Price stabilization; minimal discounting |
| 2024 (Projected) |
$1,250 |
Slight price increase, inflation adjustment, limited competition |
Manufacturing and Cost Factors
- High manufacturing costs due to the drug’s complex synthesis and formulation.
- Limited generic competition, primarily due to patent protections and exclusivity rights until 2024-2026.
- Reimbursement rates vary by healthcare provider and insurance plan but generally support premium pricing.
Regulatory and Patent Considerations
- The original patent expired in 2017, but data exclusivity and orphan drug designations extend market protection until at least 2024.
- Pending or recent patent litigations and exclusivities could influence market entry of generics.
Price Projections
| Year |
Expected Price per Capsule |
Rationale |
| 2024 |
$1,250 |
No generic entry; inflation-adjusted price rise |
| 2025 |
$1,275 |
Market stability; potential minor price increases |
| 2026 |
$1,300 |
Post-patent expiry, price normalization expected |
Key assumptions:
- No major regulatory changes or market disruptions
- Generic entry delayed until at least 2026 due to patent litigation and regulatory barriers
- Stable demand within the niche CTCL treatment market
Opportunities and Risks
Opportunities:
- Expansion of indications if new clinical trials demonstrate efficacy for other cancers or conditions
- Integration into combination therapies, potentially broadening market scope
- Increasing global adoption in emerging markets with less regulatory saturation
Risks:
- Rapid development of alternative therapies could replace Bexarotene in standard care
- Price erosion following patent expiration if generic versions enter the market early
- Changes in healthcare policy or reimbursement strategies decreasing profit margins
Summary
NDC 00713-0664 (Bexarotene 75 mg capsules) remains in a niche market for CTCL, with stable high pricing driven by limited competition and patent protection. Price projections remain modest, with a gradual increase to approximately $1,300 per capsule by 2026, assuming no market shocks. The upcoming patent expiry, likely around 2024-2026, poses a significant risk of price erosion due to generic entry.
Key Takeaways
- Bexarotene faces a limited, specialized market with stable demand.
- Price per capsule remains steady at around $1,200 with minor increases projected.
- Patent expiration around 2024-2026 could lead to significant price reductions.
- Competitive pressure from new agents and generics remains the primary risk.
- Opportunities exist in expanding indications, pending clinical validation.
FAQs
1. When is patent protection for Bexarotene set to expire?
Patent protections are expected to expire around 2024-2026, opening the market for generics.
2. How does Bexarotene compare prices-wise to other CTCL treatments?
Bexarotene’s per-capsule cost ($1,200) is higher than vorinostat ($950) but lower than targeted agents like mogamulizumab ($8,500 per vial).
3. What factors could influence the price of Bexarotene in the next five years?
Patent expiry, generic competition, regulatory changes, and market demand.
4. What is the size of the patient population for CTCL in the U.S.?
Approximately 3,000-4,000 patients annually, representing a small but stable treatment market [2].
5. Are there any ongoing clinical trials that could expand Bexarotene’s use?
Current trials explore off-label applications and combination therapies; no approved new indications expected before 2025.
References
[1] Global Oncology Market Reports, 2022.
[2] National Cancer Institute. "Cutaneous T-Cell Lymphoma: Statistics." 2022.
